Autres langues Tarsus Pharmaceuticals, Inc.

Actions

TARS

US87650L1035

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 21:52:38 05/08/2026			Varia. 5j.	Varia. 1 janv.
60,80 ^USD	-0,50%		+3,47%	-26,05%

31/07	TARSUS PHARMACEUTICALS, INC. : Mizuho Securities reste à l'achat	ZM
15/07	RxSight nomme Aziz Mottiwala au poste de PDG	MT

Autres langues

15/07	RxSight Names Aziz Mottiwala as CEO
13/07	Tarsus Pharmaceuticals, Inc. Announces Management Changes, Effective July 13, 2026
13/07	Tarsus Pharmaceuticals Appoints Neera Clase as Interim Chief Commercial Officer
13/07	Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
08/07	Tarsus Pharmaceuticals Buys iRenix Medical
08/07	Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
08/07	Tarsus Pharmaceuticals, Inc. completed the acqusisition of iRenix Medical, Inc.
08/07	Tarsus Pharmaceuticals, Inc. agreed to acquire iRenix Medical, Inc for approximately $570 million.
01/07	Tarsus Pharmaceuticals Faces Medicare Copay Allegations From Culper Research; Shares Fall
28/05	Tarsus to Participate in Upcoming Investor Conferences
14/05	Tarsus and John Cena partner to raise awareness of Demodex blepharitis, a common eyelid disease affecting approximately 25 million Americans
14/05	Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
07/05	Tarsus to Participate in Upcoming Investor Conferences
07/05	Tarsus Pharmaceuticals : Reports First Quarter 2026 Financial Results and Recent Business Achievements
07/05	Tarsus Pharmaceuticals : First Quarter 2026 Earnings Presentation
06/05	Earnings Flash (TARS) Tarsus Pharmaceuticals, Inc. Reports Q1 Revenue $162.1M, vs. FactSet Est of $149.6M
06/05	Tarsus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
06/05	Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
29/04	Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
16/04	Achieve Life Sciences, Inc. Announces Chief Executive Officer Changes
16/04	Achieve Life Sciences, Inc. Announces Executive and Board Changes
01/04	Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05, a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
31/03	Tarsus Pharmaceuticals, Inc. Doses First Participant in Phase 2 Clinical Trial of TP-05 for Potential Prevention of Lyme Disease
31/03	Tarsus Pharmaceuticals Doses First Participant in Phase 2 Lyme Disease Prevention Study
31/03	Tarsus doses first participant in Calliope, a Phase 2 clinical trial of TP-05 (lotilaner)